A Rational Ordering of the Actions of Antipsychotic Drugs

Total Page:16

File Type:pdf, Size:1020Kb

A Rational Ordering of the Actions of Antipsychotic Drugs A Rational Ordering of the Actions of Antipsychotic Drugs Glenn Schwarcz, MD Washington, DC Most major actions of the antipsychotic drugs stem from one of the four antagonistic functions common to all these drugs. Antidopaminergic activity in the mesolimbic system results in the primary desired effect, control of psychosis. Antidopamin­ ergic activity also occurs in other brain areas. Dopamine blockade in the nigrostriatal pathway results in extrapyramidal symptoms and tardive dyskinesia. Blockade in the tuberoin- fundibular tract of the hypothalamus causes elevated circulating prolactin. Central H, histaminic receptors are also blockaded by these drugs, causing sedation. The anti-alpha adrenergic activity of the antipsychotics results in orthostatic hypoten­ sion, and antimuscarinic activity results in the atropinic pic­ ture commonly seen with these drugs. The mnemonic “the anti-fours” is used to order the four major pharmacological effects: anti-dopaminergic, anti-H, histaminic, anti-alpha ad­ renergic, and anti-muscarinic. Among the most complex and theoretically de­ and dibenzoxazepines (eg, loxapine)—are similar manding medications in all of medicine are the enough in their main actions to be considered as phenothiazine-type antipsychotics. Their diverse one class. They will therefore be referred to as the and seemingly unrelated actions can overwhelm antipsychotics, as that is their best appreciated the novice as well as the experienced physician. action. This article presents an organized approach to rationally understanding the pharmacology of these medications. Although it is clear that the The "Anti-Fours" structures and minor or idiosyncratic side effects While there are numerous less frequent and of some of the antipsychotics may vary, all of the idiosyncratic side effects of the antipsychotics, major classes—phenothiazines, butyrophenones, their main actions can be broken up into four thioxanthenes, dihydroindolones (eg, molindone), major antagonistic functions, which can be nick­ named the “anti-fours.” These are (1) anti­ From the Department of Psychiatry, Howard University dopaminergic, (2) anti-H, histaminic, (3) anti-alpha School of Medicine, and St Elizabeth's Hospital, Washing­ adrenergic, and (4) anti-muscarinic. These four an­ ton, DC. Requests for reprints should be addressed to Dr. Glenn Schwarcz, O'Malley Division, St Elizabeth's Hospital, tagonistic actions constitute the crux of the action Washington, DC 20032. of all antipsychotics (Table 1). 0094-3509/82/020263-05$01.25 ® 1982 Appleton-Century-Crofts THE JOURNAL OF FAMILY PRACTICE, VOL. 14, NO. 2: 263-267, 1982 263 ACTIONS OF ANTIPSYCHOTIC DRUGS Table 1. The "Anti-Fours" Pharmacological Action Clinical Picture Anti-dopaminergic: In the m esolim bic system Antipsychotic activity In the nigrostriatum Extrapyramidal side effects and tardive dyskinesia In the hypothalam ic High prolactin syndrome with tuberoinfundibular tracts amenorrhea, galactorrhea, and gynecomastia Anti-Hi histaminic Sedation Anti-alpha adrenergic Orthostatic hypotension Anti-muscarinic Atropinic side effects Antidopaminergic elderly people, which causes primary Parkinson’s disease. Typical symptoms include rest tremor, It is well known that all drugs used to treat psy­ masked facies, shuffling gait, and muscular rigid­ choses block dopamine. It does not follow that ity. Other extrapyramidal effects of antipsychot­ dopamine overactivity is the cause of schizophre­ ics, such as akathisia and acute dystonia, are nia, although that very hypothesis, the dopamine thought to be due to diminished dopamine trans­ theory of schizophrenia, has been espoused.1 It mission in the striatum. The acute dystonias in­ may be that dopamine blockade is only indirectly clude acute spasms of muscle groups occurring related to amelioration of psychosis. Neverthe­ early (hours to days) in treatment. Examples are less, as the dopamine theory of schizophrenia is spasm of neck muscles (torticollis), of extraocular the most consistent and scientifically supported muscles (oculogyric phenomenon), of the mastica­ etiological theory of schizophrenia, the primary tory muscles (trismus), and of the back muscles antipsychotic action of antipsychotics may be en­ (opisthotonos). Clinical observation suggests that visioned by postsynaptic dopamine blockade. the less-sedating piperazine phenothiazines more Dopamine is actually blocked in three areas in often cause dystonias. In contrast, the more- the brain, giving three distinct actions common to sedating aliphatics, like chlorpromazine, tend to all antipsychotics. cause parkinsonism. In recent years, much attention has been fo­ cused on late-appearing choreoathetoid movements Dopamine Blockade in the Mesolimbic System of the tongue, mouth, and extremities, known as The limbic system and its midbrain connections tardive dyskinesia. The social and cosmetic unde­ are the seat of emotion and behavior. Specifically, it sirability of these movements is underscored by is dopamine blockade in this locality that is thought the knowledge that the syndrome is irreversible in to act against the symptoms of schizophrenia. many cases, even after the medications are with­ drawn. Theoretically, tardive dyskinesia is oppo­ site to parkinsonism and the dystonias because too Dopamine Blockade in the Nigrostriatal System much striatal dopamine, not too little, is its cause. Dopamine of the extrapyramidal system is Initially, postsynaptic dopamine blockade by likewise blockaded by all antipsychotics. De­ antipsychotic medications decreases striatal dopa­ creased dopamine transmission in the substantia mine. However, years of denervation lead to two nigra causes parkinsonism, similar to idiopathic compensatory mechanisms. First, new receptors dopamine degeneration in the substantia nigra of grow de novo postsynaptically. Second, feedback 264 THE JOURNAL OF FAMILY PRACTICE, VOL. 14, NO. 2, 1982 ACTIONS OF ANTIPSYCHOTIC DRUGS loops cause increased presynaptic dopamine re­ antidepressants is due to their H, antihistaminic lease. The net result is increasing dopamine activ­ action.2 The tricyclic antidepressants are struc­ ity that eventually overcomes drug blockade and turally very similar to the phenothiazines. They results in a high dopamine state in the striatum. were, in fact, originally synthesized in an attempt When dopamine activity becomes excessive in the to find a more effective phenothiazine. caudate nucleus, the choreoathetosis of tardive It should be appreciated that phenothiazines are dyskinesia results. Dopamine inhibits the caudate, true antihistamines.3 They are one of the five basic which itself is an inhibitory nucleus. Excessive structural classes of antihistamic drugs, the proto­ dopamine inhibition of the caudate causes disin- type in general clinical use being promethazine hibition of movements normally suppressed, with (Phenergan). Promethazine is identical to chlor­ resulting choreoathetosis. This resembles the cho­ promazine except that the three-carbon bridge be­ reoathetosis of Huntington’s disease, in which idi­ tween the tricyclic B-ring nitrogen and the amine opathic caudate degeneration similarly disinhibits side chain moiety is replaced by a two-carbon normally suppressed movements. bridge in the nonpsychoactive antihistamine pro­ The situation in the striatal disorders is actually methazine. The three-carbon bridge is necessary more complicated because it is not absolute for antipsychotic activity, occurring in all of the dopamine deficiency or excess that causes the ex- psychoactively efficacious phenothiazines. trapyramidal signs; rather, it is a change in the The necessary structure for antihistaminic ac­ dopamine-acetylcholine ratio. Thus, if the cholin­ tivity is a substituted ethylamine.3 The phenothia­ ergic system is diminished to the same extent as zine structure, with the tricyclic ring linked to the the dopaminergic system, as by benztropine side-chain ethylamine, is a perfect example of this (Cogentin), parkinsonism and dystonias will not antihistamine structure. How H, antihistamines occur. Likewise, if the cholinergic system can be depress the central nervous system and cause se­ enhanced by physostigmine, cholinergic activity dation is not understood from a structure activity temporarily rises to match the enhanced dopamine viewpoint,3 but it is well established that they do activity of tardive dyskinesia, and the choreoathe­ cause sedation, as anyone with hayfever knows. tosis transiently disappears. In this light, anticho­ Thus, by recognizing that phenothiazines, the pro­ linergic drugs worsen the low acetylcholine-high totype antipsychotics, are antihistamines, their dopamine balance and worsen tardive dyskinesia. sedative action can easily be appreciated and con­ ceptualized. Dopamine Blockade in the Tuberoinfundibular System Dopamine, blocked in these tracts in the hypo­ Anti-Alpha Adrenergic thalamus, causes the well-known rise in prolactin The adrenergic blocking action of antipsychot­ induced by all antipsychotic drugs. Since dopa­ ics is well documented as causing orthostatic hy­ mine causes tonic inhibition of prolactin, blocking potension. The low-potency antipsychotics, such dopamine allows dysinhibition and tonic release as chlorpromazine (Thorazine) and thioridazine of prolactin. This results in galactorrhea, gyneco­ (Mellaril), are especially potent in this activity and mastia, amenorrhea, and the libidinal disturbances in causing orthostasis.4 Since alpha receptor stim­ well known with antipsychotics. ulation causes
Recommended publications
  • Deanxit SPC.Pdf
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Deanxit film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Flupentixol 0.5 mg (as 0.584 mg flupentixol dihydrochloride) Melitracen 10 mg (as 11.25 mg melitracen hydrochloride) Excipients with known effect: Lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets. Round, biconvex, cyclamen, film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Anxiety Depression Asthenia. Neurasthenia. Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. 4.2 Posology and method of administration Posology Adults Usually 2 tablets daily: morning and noon. In severe cases the morning dose may be increased to 2 tablets. The maximum dose is 4 tablets daily. Older people (> 65 years) 1 tablet in the morning. In severe cases 1 tablet in the morning and 1 at noon. Maintenance dose: Usually 1 tablet in the morning. SPC Portrait-REG_00051968 20v038 Page 1 of 10 In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended. Paediatric population Children and adolescents (<18 years) Deanxit is not recommended for use in children and adolescents due to lack of data on safety and efficacy. Reduced renal function Deanxit can be given in the recommended doses. Reduced liver function Deanxit can be given in the recommended doses. Method of administration The tablets are swallowed with water. 4.3 Contraindications Hypersensitivity to flupentixol and melitracen or to any of the excipients listed in section 6.1.
    [Show full text]
  • Thioxanthene Derivates As Sole Anti-Infective Agents
    (19) & (11) EP 2 114 406 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/496 (2006.01) A61P 31/04 (2006.01) 25.05.2011 Bulletin 2011/21 A61P 33/00 (2006.01) (21) Application number: 08700129.3 (86) International application number: PCT/DK2008/000005 (22) Date of filing: 07.01.2008 (87) International publication number: WO 2008/080408 (10.07.2008 Gazette 2008/28) (54) THIOXANTHENE DERIVATESAS SOLEANTI- INFECTIVEAGENTS FORUSE INT HE TREATMENT OF INFECTIOUS DISEASES THIOXANTHEN-DERIVATE ALS ALLEINVERTRETER DER ANTIINFEKTIVA ZUR VERWENDUNG IN DER BEHANDLUNG VON INFEKTIONSKRANKHEITEN DÉRIVÉS DE THIOXANTHÈNE COMME SEULS AGENTS ANTIINFECTIEUX POUR LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES INFECTIEUSES (84) Designated Contracting States: • MORTENSEN I ET AL: "THE ANTIBACTERIAL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR ACTIVITY OF THE HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT PSYCHOPHARMACOLOGICAL AGENT RO SE SI SK TR CLOPENTHIXOL AND ITS TWO MAIN METABOLITES" ACTA PATHOLOGICA (30) Priority: 05.01.2007 PCT/DK2007/000006 MICROBIOLOGICASCANDINAVICA, SECTION B, XX, XX, vol. 95B, no. 6, 1987, pages 355-359, (43) Date of publication of application: XP008066133 ISSN: 0108-0180 11.11.2009 Bulletin 2009/46 • KOCISKO ET AL: "Comparison of protease- resistant prion protein inhibitors in cell cultures (60) Divisional application: infected with two strains of mouse and sheep 10181816.9 / 2 301 545 scrapie" NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 388, no. 2, 11 November 2005 (2005-11-11), (73) Proprietor: BKG Pharma ApS pages 106-111, XP005042190 ISSN: 0304-3940 2920 Charlottenlund (DK) • KAISER C ET AL: "Analogs of phenothiazines.
    [Show full text]
  • Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity
    pharmaceuticals Article Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity Michele Tonelli 1,* , Anna Sparatore 2,* , Nicoletta Basilico 3,* , Loredana Cavicchini 3, Silvia Parapini 4 , Bruno Tasso 1 , Erik Laurini 5 , Sabrina Pricl 5,6 , Vito Boido 1 and Fabio Sparatore 1 1 Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV, 3, 16132 Genova, Italy; [email protected] (B.T.); [email protected] (V.B.); [email protected] (F.S.) 2 Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli 25, 20133 Milano, Italy 3 Dipartimento di Scienze Biomediche Chirurgiche e Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milano, Italy; [email protected] 4 Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milano, Italy; [email protected] 5 Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, Piazzale Europa 1, 34127 Trieste, Italy; [email protected] (E.L.); [email protected] (S.P.) 6 Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland * Correspondence: [email protected] (M.T.); [email protected] (A.S.); [email protected] (N.B.) Received: 4 October 2020; Accepted: 21 October 2020; Published: 25 October 2020 Abstract: Leishmaniases are neglected diseases that are endemic in many tropical and sub-tropical Countries. Therapy is based on different classes of drugs which are burdened by severe side effects, occurrence of resistance and high costs, thereby creating the need for more efficacious, safer and inexpensive drugs.
    [Show full text]
  • N-Alkylamino Derivates of Aromatic, Tricyclic Compounds in the Treatment of Drug-Resistant Protozoal Infections
    Europaisches Patentamt 0 338 532 European Patent Office Qv Publication number: A2 Office europeen des brevets EUROPEAN PATENT APPLICATION 31/54 © Application number: 89107027.8 © mt.ci.4.A61K 31/38 , A61K @ Date of filing: 19.04.89 © Priority: 20.04.88 US 183858 © Applicant: MERRELL DOW 12.09.88 US 243524 PHARMACEUTICALS INC. 2110 East Galbraith Road @. Date of publication of application: Cincinnati Ohio 45215-6300(US) 25.10.89 Bulletin 89/43 © Inventor: Bitonti, Alan J. © Designated Contracting States: 7854 Carraway Court AT BE CH DE ES FR GB GR IT LI LU NL SE Maineville Ohio 45039(US) Inventor: McCann, Peter P. 3782 Cooper Road Cincinnati Ohio 45241 (US) Inventor: Sjoerdsma, Albert 5475 Waring Drive Cincinnati Ohio 45243(US) © Representative: Vossius & Partner Siebertstrasse 4 P.O. Box 86 07 67 D-8000 Munchen 86(DE) © N-alkylamino derivates of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections. © Drug-resistant protozoal infection, particularly, drug-resistant malarial infection in humans, can be effectively treated with standard antiprotozoal agents if administered in conjunction with a tricyclic N-aminoalkyi iminodiben- zyl, dibenzylcycloheptane and cycloheptene, phenothiazine, dibenzoxazepine, dibenzoxepine, or thioxanthene derivative. CM < CM CO in oo CO CO LU Xerox Copy Centre EP 0 338 532 A2 N-ALKYLAMINO DERIVATIVES OF AROMATIC, TRICYCLIC COMPOUNDS IN THE TREATMENT OF DRUG- RESISTANT PROTOZOAL INFECTIONS This invention relates to the use of certain N-(aminoalkyl) derivatives of iminodibenzyl, dibenzyl- cycioheptane and cycloheptene, phenothiazine, dibenzoxazepine, dibenzoxepine, and thioxanthene in the treatment of drug-resistant malaria and in the treatment of other drug-resistant protozoal infections.
    [Show full text]
  • < MOH Approved Drugs List >
    Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 1 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph. System : GASTRO-INTESTINAL SYSTEM 1 Main Group : ANTACIDS 1 Sub Group : ALUMINIUM COMPOUNDS 1 03000000105 ALUMINIUM HYDROXIDE GEL, DRIED 475 MG. CAPSULE Desirable Cat_C Not H/C Item 2 Sub Group : ANTACID COMPOUND PREPARATIONS 2 02000000079 ANTACID SUSPENSION (ALUMINIUM HYDROXIDE + BOTTLE Desirable MAGNESIUM HYDROXIDE OR TRISILICATE) 100 - 200 Cat_A ML. B0TTLE. H/C Item 3 03000000173 ANTACID TABLET (ALUMINIUM HYDROXIDE + TABLET/CAP Desirable MAGNESIUM HYDROXIDE OR TRISILICATE). Cat_A H/C Item 2 Main Group : ANTISPASMODICS 1 Sub Group : ANTIMUSCARINICS 4 01000000304 HYOSCINE N BUTYLBROMIDE 20MG/ML. 1ML. AMPOULE Essantial Cat_A H/C Item 5 03000000640 HYOSCINE N BUTYL BROMIDE 10MG. TABLET/CAP Essantial Cat_A H/C Item 6 020D0000063 ANTISPASMODIC DROPS 15ML-25ML. BOTTLE Desirable Cat_C Not H/C Item 2 Sub Group : OTHER ANTISPASMODIC AND MOTILITY STIMULANT 7 03000001245 MEBEVERINE HYDROCHLORIDE 100 MG - 135 MG. TABLET/CAP Essantial Cat_B Not H/C Item Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 2 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph.
    [Show full text]
  • ( 12 ) United States Patent
    US010308645B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,308 ,645 B2 Liverton et al . (45 ) Date of Patent : Jun . 4 , 2019 ( 54 ) PIPERIDINE OXADIAZOLE AND 8 , 399 ,281 B1 3 / 2013 Patterson et al . 8 , 399 ,494 B2 3 / 2013 Bergman et al. THIADIAZOLE OREXIN RECEPTOR 8 . 466 , 281 B2 6 / 2013 Coleman et al. ANTAGONISTS 8 ,618 , 102 B2 12 / 2013 Coleman et al. 8 ,623 ,863 B2 1 / 2014 Coleman et al. (71 ) Applicant : MERCK SHARP & DOHME CORP ., 8 ,669 , 272 B2 3 / 2014 Breslin et al . 8 ,685 , 961 B2 4 / 2014 Brashear et al. Rahway, NJ (US ) 8 ,710 , 076 B2 4 / 2014 Breslin et al. 8 , 940 , 898 B2 1 / 2015 Kuduk et al . (72 ) Inventors: Nigel Liverton , Harleysville , PA (US ) ; 9 , 029 , 364 B2 5 /2015 Kuduk et al. Scott D . Kuduk , Harleysville , PA (US ) ; 9 , 156 ,819 B2 10 / 2015 Kuduk et al . 9 , 546 , 152 B2 1 /2017 Kuduk et al. Yunfu Luo , Shanghai ( CN ) ; Na Meng , 9 ,550 ,786 B2 1 /2017 Cooke et al . Shanghai (CN ) ; Tingting Yu , Shanghai 9 , 556 , 145 B2 1 / 2017 Kuduk et al . (CN ) 9 ,556 , 190 B2 1 / 2017 Kuduk et al . 9 ,586 ,934 B2 3 / 2017 Kuduk et al. ( 73 ) Assignee : Merck Sharp & Dohme Corp . , 9 , 586 , 950 B2 3 /2017 Kuduk et al. 9 ,617 , 246 B2 4 /2017 Kuduk et al. Rahway , NJ (US ) 9 ,624 , 197 B2 4 / 2017 Kuduk et al . 2009 / 0215822 Al 8 / 2009 Farina et al . ( * ) Notice : Subject to any disclaimer, the term of this 2010 / 0029736 A1 2 / 2010 Cox et al .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.486,437 B2 Rogowski Et Al
    USOO94864-37B2 (12) United States Patent (10) Patent No.: US 9.486,437 B2 Rogowski et al. (45) Date of Patent: *Nov. 8, 2016 (54) METHODS OF USING LOW-DOSE DOXEPIN 5,858.412 A 1/1999 Staniforth et al. FOR THE IMPROVEMENT OF SLEEP 5,866,166 A 2f1999 Staniforth et al. 5.948,438 A 9, 1999 Staniforth et al. (71) Applicants: Pernix Sleep, Inc., Morristown, NJ 5,965,166 A 10, 1999 Hunter et al. (US); ProCom One, Inc., San Marcos, 6,103,219 A 8, 2000 Sherwood et al. TX (US) 6,106,865 A 8, 2000 Staniforth et al. 6,211,229 B1 4/2001 Kavey (72) Inventors: Roberta L. Rogowski, Rancho Santa 6,217,907 B1 4/2001 Hunter et al. Fe, CA (US); Susan E. Dubé, Carlsbad, 6,217.909 B1 4/2001 Sherwood et al. CA (US); Philip Jochelson, San Diego, 6,219,674 B1 4/2001 Classen CA (US); Neil B. Kavey, Chappaqua, 6,344,487 B1 2/2002 Kavey 6,358,533 B2 3/2002 Sherwood et al. NY (US) 6,391,337 B2 5, 2002 Hunter et al. (73) Assignees: Pernix Sleep, Inc., Morristown, NJ 6,395,303 B1 5, 2002 Staniforth et al. (US); ProCom One, Inc., San Marcos, 6,403,597 B1 6/2002 Wilson et al. 6,407,128 B1 6/2002 Scaife et al. TX (US) 6,471.994 B1 10/2002 Staniforth et al. 6,521,261 B2 2/2003 Sherwood et al. (*) Notice: Subject to any disclaimer, the term of this 6,584,472 B2 6/2003 Classen patent is extended or adjusted under 35 6,683,102 B2 1/2004 Scaife et al.
    [Show full text]
  • Long-Acting Injectable Antipsychotics. Review and Recent Developments
    Review Article Monica Zolezzi, BPharm, MSc. ABSTRACT Long-acting injectable antipsychotics, also known as "depots", were developed in the late 1960s as an attempt to improve compliance and long-term management of schizophrenia. Despite their availability for over 30 years, guidelines for their use and data on patients for whom long-acting injectable antipsychotics are most indicated are sparse and vary considerably. A review of the perceived advantages and disadvantages of using long-acting injectable antipsychotics is provided in this article, as well as a review of the literature to update clinicians on the current advances of this therapeutic option to optimize compliance and long-term management of chronic schizophrenia. Neurosciences 2005; Vol. 10 (2): 126-131 chizophrenia is a chronic disorder for which it is hydrolyze the esterified compound and liberates the Swell recognized that lifelong treatment with parent antipsychotic.2,9,10 Although depot antipsychotics is necessary. Although quite antipsychotics have been available for over 30 successful in treating and preventing relapses,1,2 years, guidelines for their use and data on patients antipsychotics are not readily accepted by patients, for whom long-acting injectables are most indicated thus, non-compliance is common.3,4 Thus, are sparse and vary considerably. In addition, long-acting injectable forms of these medications despite the fact that the use of depot antipsychotics were developed in an attempt to help medication has been extensively promoted to overcome patient compliance
    [Show full text]
  • C. VA Drug Classification System
    Appendix C C. VA Drug Classification System Introduction The Department of Veterans Affairs Drug Classification system was developed to provide a systematic management approach to the classification of medications, including investigational and over-the-counter drugs, prosthetic items, and expendable supplies. The system is designed to • support inpatient and outpatient pharmacy activities; • facilitate identification of drug-drug, drug-allergy, drug-lab, and drug-food interactions; • uphold requirements for inventory accountability; • substantiate and improve all patient medication-related activity; • provide an improved database to assist the health care provider; • provide a coordinated method of database communication for VA management; • facilitate monitoring of investigational drugs; and • facilitate control of prosthetic and supply items. Each five-character alpha-numeric code specifies a broad classification and a specific type of product. The first two characters are letters and form the mnemonic for the major classification (e.g., AM for antimicrobials). Characters 3 through 5 are numbers and form the basis for subclassification. For example, the classification system for the penicillins is as follows. AM000 ANTIMICROBIALS AM050 Penicillins AM051 Penicillin-G Related Penicillins AM052 Penicillins, Amino Derivatives AM053 Penicillinase-Resistant Penicillins AM054 Extended Spectrum Penicillins Descriptive comments are included only when the classification system itself is not self- explanatory. The VA Drug Classification system
    [Show full text]
  • Myelogram-Medications-To-Avoid.Pdf
    Medication to be held 48 Banaflex /skeletal muscle relaxer Clozaril/antischizophenia HOURS BEFORE AND 24 HOURS Bancap/contains caffei Cogentin/antidyskinectic/ant AFTER MYELOGRAM Banzel/seizure adjunct iemetic/antipsychotic Updated December 2016 BC powder/ contains caffeine Compazine/phenothiazine Belviq/appetite suppressant Concerta/CNS stimulant Abilify / antipsychotic Bevespi contains formoterol Contrave/antidepressant Acetophenazine/ antipsychotic Benzphetamine/appetite Cyclizine/ antiemetic Adderall/amphetamine and suppressant antivertigo agent dextroamphetamine Bismuth subcitrate potassium/ Cyclobenzaprine/muscle Adipex-P/stimulant/ anorectic mineral relaxer Adsuva/antidepressant Bonine/meclicine Cylert/ADHD agent Adphen/ /antidepressant Bontril/appetite suppressant Cymbalta/antidepressant/tri appetite suppressant Bontril PDM/appetite suppressant cyclic Adipost/ appetite suppressants, Bortezomib/antineoplastics Sympathomimetic (Systemic Brintxelli / antidepressant Adrafinil/cognitive enhancer Bucladin-S softab/antiemetic Dapex/appetite suppressant Alatrofloxacin/ antibacterial antivertigo Dayquil/contains caffeine Aliskiren Bucet/contains caffeine Darvon 65/contain caffeine Hemifumarate/antihypertensive Buclizine/antiemetic/antivertigo Daytrana/CNS stimulant direct renal inhibitor / Budeption/antidepressant Desipramine/tricyclic/antide Alsuma/s Buphenamine/appetite suppressant pressant Amaphen/ barbituate Buproban/antidepressantr Desoxyn/amphetamine Amitriptyline/ tricyclic BupropionBuffets/caffeine Desvenlafaxine succinate/ antidepressant
    [Show full text]
  • Tardive Dyskinesia
    Task Force Reports This is the eighteenth in a series of reports approved by the Board of Trustees of the American Psychiatric Association to give wider dissemination to the findings of APA's many commissions, committees, and task forces that are called upon to evaluate the state of the art in a problem area of current concern to the profession, to related disciplines, and to the public. The findings, opinions, and conclusions of the report do not necessarily represent the views of the officers, trustees, or all members of the Association. Each report, however, does represent the thoughtful judgment and findings of the task force of experts who composed it. These reports are considered a substantive contribution to the ongoing analysis and evaluation of problems, programs, issues, and practices in a given area of concern. Alan A. Stone, M.D. President, APA, 1979-80 Library of Congress Catalogue No. 80-65372 Copyright 1980 by the American Psychiatric Association 1400 K Street, N.W., Washington, D.C. 20005 Printed in U.S.A. 2nd Printing October, 1983 TARDIVE DYSKINESIA Report of the American Psychiatric Association Task Force on Late Neurological Effects of Antipsychotic Drugs Ross J. Baldessarini, M.D., Chairperson Jonathan O. Cole, M.D. John M. Davis, M.D. George Gardos, M.D., Consultant Sheldon H. Preskorn, M.D., Falk Fellow George M. Simpson, M.D. Daniel Tarsy, M.D., Invited Neurologist Approved for Publication by the Council on Research and Development John M. Davis, M.D., Chairperson Charles Gaitz, M.D. Edward Joel Sachar, M.D. George Winokur, M.D.
    [Show full text]
  • United States Patent Office Patented Aug
    3,524,000 United States Patent Office Patented Aug. 11, 1970 2 3,524,000 pounds with the substantial absence of significant toxic ANTHELMINTC COMPOSITIONS AND effects. Still another object is to provide a method for METHOD OF USING SAME treating helminthiasis with tricyclic compounds together John R. Egerton, Neshanic Station, and Joseph Di Netta, With anthelmintically active 2-substituted benzimidazoles Watchung, N.J., assignors to Merck & Co., Inc., Rah wherein the tricyclic compounds enhance the activity of way, N.J., a corporation of New Jersey the benzimidazoles. These and other objects will appear No Drawing. Continuation-in-part of application Ser. No. from the detailed description which follows. 439,926, Mar. 15, 1965. This application Oct. 20, 1967, According to the present invention, it has been sur Ser. No. 676,697 Int, C.A01n 9/22 A61d 7/00 A61k27/00 prisingly discovered that the anthelmintic activity of 2-sub O stituted benzimidazoles can be greatly enhanced when the U.S. C. 424-267 13 Claims benzimidazole is administered to the host animal in the presence of certain classes of tricyclic compounds. Thus, in one of its preferred aspects, the invention provides ABSTRACT OF THE DISCLOSURE novel 2-component compositions wherein one component The anthelmintic activity of 2-substituted benzimida is at least one of certain tricyclic compounds and the zoles is greatly enhanced when the benzimidazole is ad other component is at least one anthelmintically active ministered to the host animal in the presence of a tricyclic 2-substituted benzimidazole. The 2-substituted benzimida compound selected from the group consisting of dibenzo - Zoles contemplated for use in the present invention have cycloheptenes and thioxanthenes.
    [Show full text]